modelJ04AK02

Diagram of J04AK02

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:Ethambutol
ATC code:J04AK02
route:oral
compartments:1
dosage:1200mg
volume of distribution:1.6L
clearance:95mL/min
other parameters in model implementation

Ethambutol is an oral antimycobacterial agent primarily used in the treatment of tuberculosis, usually in combination with other antituberculosis agents. It is approved and widely used today and works by inhibiting cell wall synthesis in Mycobacterium species.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers after oral administration.

References

  1. Sundell, J, et al., & Ashton, M (2020). Population Pharmacokinetics and Pharmacogenetics of Ethambutol in Adult Patients Coinfected with Tuberculosis and HIV. Antimicrobial agents and chemotherapy 64(2) –. DOI:10.1128/AAC.01583-19 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31712201

  2. Jönsson, S, et al., & McIlleron, H (2011). Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrobial agents and chemotherapy 55(9) 4230–4237. DOI:10.1128/AAC.00274-11 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21690284

  3. Chen, C, et al., & Simonsson, US (2016). Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 93 319–333. DOI:10.1016/j.ejps.2016.07.017 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27473307

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)